Pluri (PLUR) Non-Current Debt (2021 - 2025)
Pluri (PLUR) posted quarterly Non-Current Debt of $24.9 million for Q1 2025, up 3.67% year-over-year from $24.1 million in Q1 2024, and up 4.83% quarter-over-quarter from $23.8 million in Q4 2024.
Pluri (PLUR) Non-Current Debt (2021 - 2025) Analysis & Trends
Pluri (PLUR) has reported Non-Current Debt for 5 consecutive years, with $24.9 million the latest figure, recorded in Q1 2025.
- In Q1 2025, Non-Current Debt rose 3.67% year-over-year to $24.9 million; the TTM figure through Mar 2025 stood at $24.9 million (up 3.67% YoY), while the FY2024 annual figure was $24.0 million, up 2.11% from the prior year.
- Non-Current Debt advanced to $24.9 million in Q1 2025 per PLUR's latest filing, from $23.8 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $25.4 million in Q3 2024 and bottomed at $20.7 million in Q3 2022.
- Historically, Non-Current Debt has averaged $23.4 million across 5 years, with a median of $23.5 million in 2021.
- Annual changes were most pronounced in 2022 — Non-Current Debt declined 11.61% — and 2023, when it climbed 11.82%.
- Pluri's Non-Current Debt stood at $23.2 million in 2021, then dropped by 2.09% to $22.7 million in 2022, then climbed by 7.61% to $24.4 million in 2023, then fell by 2.47% to $23.8 million in 2024, then grew by 4.83% to $24.9 million in 2025.
- Business Quant data shows PLUR's Non-Current Debt at $24.9 million in Q1 2025, $23.8 million in Q4 2024, and $25.4 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | Pluri | 16.21 Mn | 3.72 Mn | 86,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 24.95 Mn |
| Dec 31, 2024 | 23.80 Mn |
| Sep 30, 2024 | 25.37 Mn |
| Jun 30, 2024 | 24.03 Mn |
| Mar 31, 2024 | 24.07 Mn |
| Dec 31, 2023 | 24.40 Mn |
| Sep 30, 2023 | 23.17 Mn |
| Jun 30, 2023 | 23.53 Mn |
| Mar 31, 2023 | 23.35 Mn |
| Dec 31, 2022 | 22.68 Mn |
| Sep 30, 2022 | 20.72 Mn |
| Jun 30, 2022 | 21.68 Mn |
| Mar 31, 2022 | 22.92 Mn |
| Dec 31, 2021 | 23.16 Mn |
| Sep 30, 2021 | 23.44 Mn |
| Jun 30, 2021 | 23.85 Mn |